Nehal Gupta

Nehal Gupta has a strong background in scientific research, primarily focusing on oncology. They began their work experience as a Research Assistant at Texas Tech University Health Sciences Center in 2014, where they conducted research on paclitaxel resistance in metastatic breast cancer and identified penfluridol as a potential therapeutic agent. They also screened anti-protozoal drugs for their cytotoxic effects in breast cancer cell lines.

In 2019, Gupta joined the University of California, San Francisco as a Postdoctoral Research Scientist. During their time there, they studied the cross-talk between the transcriptional repressor Capicua (CIC) and ETS-2 repressor factor (ERF) in tumor progression and metastasis. They also identified a novel subtype of prostate cancer with co-occurring ERF-CIC alterations, which had worse clinical outcomes.

Most recently, Gupta joined Nereid Therapeutics in 2022 as a Scientist in the Oncology division. Additional details about their role at Nereid Therapeutics are not provided.

Nehal Gupta's education history includes earning a Bachelor of Pharmacy (B.Pharm.) degree in Pharmaceutical Sciences from Devi Ahilya Vishwavidyalaya, which was completed from 2008 to 2012. Subsequently, Nehal completed a Master of Pharmacy degree in Pharmaceutical Sciences at B. K. mody govt. pharmacy college from 2012 to 2014. Lastly, Nehal pursued a Doctor of Philosophy (Ph.D.) degree in Cell/Cellular and Molecular Biology at Texas Tech University Health Sciences Center, which was completed from 2014 to 2019.